Alliqua BioMedical, Inc. is a medical technology company specializing in advanced wound care, dermatological regeneration and aesthetic medicine solutions. The company develops, markets and distributes a portfolio of products designed to support tissue repair, promote healing and reduce scarring in acute and chronic wounds. Its offerings include proprietary collagen-based dressings, hydrogels and cell-based therapy analogues tailored to various stages of the wound-healing process.
Among Alliqua’s flagship products is the Microlyte® MIST system, a handheld ultrasonic device that delivers a non-invasive saline mist to clean and debride wounds. The company also offers OmniSurg™ collagen matrix products for surgical and traumatic wound sites, and Neogenica® skin regeneration solutions for aesthetic and dermatology applications. These technologies are intended to enhance cellular regeneration, manage exudate and maintain an optimal wound environment.
Founded under the name ADY Holdings, Inc., the company rebranded as Alliqua BioMedical in 2020 to better reflect its focus on biological and regenerative therapies. Through strategic acquisitions and internal product development, Alliqua has broadened its portfolio to serve hospitals, wound care centers, dermatology clinics and physician offices. Its products are distributed across the United States via direct sales representatives and through a network of commercial partners in select international markets.
Alliqua’s leadership team combines experience in medical device commercialization, life sciences research and regulatory affairs. Guided by a board of directors with extensive backgrounds in health care and applied biotechnology, the company continues to invest in clinical studies and product innovation aimed at addressing unmet needs in wound management and aesthetic dermatology.
AI Generated. May Contain Errors.
